KPTI News and Press, Karyopharm Therapeutics Inc. From 01/24/19

Never promote someone who hasn't made some bad mistakes, because if you do, you are promoting someone who has never done anything. - Philip Fisher Karyopharm Therapeutics (NASDAQ: KPTI ) is a highly promising cancer medicine innovator. Despite that the stock is trading on a downtrend in ...

NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, Janua...

Karyopharm Therapeutics (NASDAQ: KPTI ) reports positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, an, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with relapsed or refractory diffuse larg...

-- 29.6% Overall Response Rate Including 9.6% Complete Response Rate -- -- Amongst the Patients with Complete or Partial Response, Median Duration of Response was 9.2 Months and Median Overall Survival was 29.7 months -- -- Company Plans to Submit New Drug Ap...

NEWTON, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral S...

NEWTON, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, Novemb...

Ceremony to Commemorate Five-Year Listing Anniversary NEWTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and ...

NEWTON, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 127,500 shares o...

--  Top-line Results from Phase 2b SADAL Study in DLBCL to be Presented --  --  Additional Results from the Pivotal Phase 2b STORM Study in Penta-Refractory Multiple Myeloma and Updated Phase 1b/2 STOMP Data in Relapsed or Refractory Multiple Myeloma to be Highlighted in ...

We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...